Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021
William B. Feldman, S. Sean Tu, Rasha Alhiary, Aaron S. Kesselheim, Olivier J. Wouters
Abstract
This study quantifies the revenue earned on all brand-name inhalers approved by the US Food and Drug Administration from 2000 to 2021 and compared earnings before and after expiration of primary patents on these products.
Topics & Concepts
MedicineExpirationFood and drug administrationRevenueEarningsExpiration datePrimary careFinanceFamily medicinePharmacologyInternal medicineBusinessChemistryFood scienceRespiratory systemInhalation and Respiratory Drug Delivery